PET/CT
PET/CT is an intervention with 130 clinical trials. Currently 26 active trials ongoing. Historical success rate of 73.3%.
Success Metrics
Based on 44 completed trials
Phase Distribution
Phase Distribution
25
Early Stage
20
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
71.0%
44 of 62 finished
29.0%
18 ended early
26
trials recruiting
130
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
Pembrolizumab In Central Nervous System Metastases
PSMA PET Imaging of Recurrent Prostate Cancer
A Study of a New PET Scanner in People With Cancer
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Clinical Trials (130)
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
Pembrolizumab In Central Nervous System Metastases
PSMA PET Imaging of Recurrent Prostate Cancer
A Study of a New PET Scanner in People With Cancer
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
64Cu-LLP2A for Imaging Hematologic Malignancies
A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
Imaging of Endometriosis With Total-body PET-CT (PET-Endo)
Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection
CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 130